Panbela Therapeutics Inc. (PBLA) Receives Nasdaq Delisting Determination

On March 5, 2024, The Nasdaq Stock Market LLC (“Nasdaq”) notified Panbela Therapeutics Inc. (NASDAQ: PBLA) that the Nasdaq Hearings Panel (the “Panel”) has determined to delist the Company’s common stock and that trading of the Company’s securities will be suspended at the open of trading on March 7, 2024. Nasdaq will complete the delisting by filing a Form 25 Notification of Delisting with the U.S. Securities and Exchange Commission (the “SEC”) after applicable appeal periods have lapsed. In the interim, the Company expects its common stock will be eligible for quotation on the OTC Pink Market under its existing symbol, “PBLA.”

The Panel reached its decision because the Company is in violation of the minimum $2.5 million stockholders equity requirement in Listing Rule 5550(b)(1) and unable to comply with any of the alternative requirements in Listing Rule 5550(b). The Company has 15 days after the date it received notice of the Panel’s decision to request that the Nasdaq Listing and Hearing Review Council review the decision, or the Council may, on its own motion, determine to review the Panel’s decision within 45 calendar days after the Company was notified of the decision.

The Company plans to continue to file its required periodic reports and other filings with the SEC.

You May Also Be Interested In

• Real and RE/MAX Holdings set Aug. 24 merger closing date
• Singularity Future Technology prices $5M direct offering at $3.20 per share
• ESS Tech launches $3.2M stock offering at $0.50 per share